CLINICAL TRIALS PROFILE FOR TIPRANAVIR

505(b)(2) Clinical Trials for Tipranavir

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT02244190 ↗	Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers	Completed	Boehringer Ingelheim	Phase 1	2008-04-01	To establish the bioequivalence of the new tipranavir oral solution formulation with the current tipranavir oral solution formulation following single-dose administration. In each case, 500 mg tipranavir was coadministered with 200 mg ritonavir.

All Clinical Trials for Tipranavir

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00034866 ↗	Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals	Completed	Boehringer Ingelheim	Phase 2	2002-04-01	The purpose of this research study is to determine which of three different dose combinations of tipranavir and ritonavir, when taken with a standard approved anti-HIV drug therapy, is most effective and safe. Tipranavir is an investigational protease inhibitor which has been demonstrated to have in vitro activity against HIV-1.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	PENTA Foundation	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00054717 ↗	Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)	Completed	Boehringer Ingelheim	Phase 3	2003-01-01	Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients.

Clinical Trial Conditions for Tipranavir

Condition Name

Condition Name for Tipranavir
Intervention	Trials
HIV Infections	34
Healthy	26
Hepatic Insufficiency	2
Infection, Human Immunodeficiency Virus	2

Condition MeSH

Condition MeSH for Tipranavir
Intervention	Trials
HIV Infections	37
Infections	6
Communicable Diseases	6
Infection	5

Clinical Trial Locations for Tipranavir

Trials by Country

Trials by Country for Tipranavir
Location	Trials
United States	274
Canada	34
Australia	15
Germany	13
Spain	12

Trials by US State

Trials by US State for Tipranavir
Location	Trials
Texas	15
Florida	13
California	13
North Carolina	12
New York	12

Clinical Trial Progress for Tipranavir

Clinical Trial Phase

Clinical Trial Phase for Tipranavir
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	8
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for Tipranavir
Clinical Trial Phase	Trials
Completed	54
Terminated	9
Approved for marketing	3

Clinical Trial Sponsors for Tipranavir

Sponsor Name

Sponsor Name for Tipranavir
Sponsor	Trials
Boehringer Ingelheim	56
GlaxoSmithKline	3
Germans Trias i Pujol Hospital	2

Sponsor Type

Sponsor Type for Tipranavir
Sponsor	Trials
Industry	64
Other	18
NIH	5

TIPRANAVIR: Clinical Trials Update, Market Analysis, and Forecast

Last updated: January 31, 2026

Summary

Tipranavir (brand name: Aptivus) is a non-peptidic protease inhibitor developed for the treatment of HIV-1 infection. Originally approved by the U.S. Food and Drug Administration (FDA) in 2005, Tipranavir is used primarily for treatment-experienced patients with resistant HIV strains. This report provides a comprehensive review of current clinical trial statuses, recent developments, market dynamics, competitive landscape, and future projections.

---

Clinical Trials Update for Tipranavir

Current Clinical Trial Landscape

As of Q1 2023, there are no active Phase 3 or Phase 4 trials specifically focusing on Tipranavir. Historically, the drug has completed its primary clinical trials and gained regulatory approval based on studies demonstrating efficacy in multi-drug resistant HIV cases.

Trial Phase	Number of Trials	Focus Areas	Status
Phase 1	0	N/A	Completed
Phase 2	2	Pharmacokinetics, safety in special populations	Completed
Phase 3	0	N/A	Completed
Post-Marketing	0	Real-world effectiveness & safety (Pharmacovigilance)	Ongoing (Post-marketing surveillance)

Key Clinical Data:

• Efficacy: Clinical trials, such as the later-stage studies leading to its 2005 approval, demonstrated that Tipranavir effectively reduces viral load in multi-drug resistant HIV-1 cases.

• Safety: Common adverse effects include hepatic enzyme elevations, diarrhea, and intracranial hemorrhage risks, warranting monitoring during therapy.

Recent Research & Developments

• New Formulations: Limited activity has been directed toward novel oral formulations or injectable versions; some preclinical research is underway but not in advanced clinical phases.

• Combination Therapy Trials: A few studies investigate Tipranavir as part of combination regimens with newer agents, potentially enhancing resistance profiles. However, no recent large-scale trials have been published.

• Regulatory Updates: No recent updates from FDA or EMA indicating new indications or label expansions.

Regulatory Status and Approval

Region	Approval Date	Indications	Notes
USA	2005	HIV-1 Infection	Approved for multi-resistant cases
EU	2006	HIV-1 Infection	Similar indication
Other Markets	Varies	Similar	Limited approval, often off-label use

---

Market Analysis of Tipranavir

Market Overview

Despite its early approval, Tipranavir’s market share has diminished owing to:

• Availability of newer agents with better tolerability profiles and simplified dosing (e.g., Darunavir, Rilpivirine).
• Reserving use for highly resistant HIV strains, narrowing its patient base.
• Market presence limited primarily to select markets with resource constraints or extensive resistance cases.

Market Size & Revenue

Parameter	2021	2022 (est.)	2023 Projection	Remarks
Global HIV Protease Inhibitor Market	$4.5 billion	$4.8 billion	$5.2 billion	Expected CAGR: 4% (2022–2027)
Tipranavir's Market Share	~2–3%	↓ 1.5%	↓ further	Declining due to newer therapies
Revenue (Global)	~$100 million	~$72 million	~$62 million	Decline driven by decreased prescribing

Competitive Landscape

Major Competitors	Key Attributes	Market Position
Darunavir	Improved tolerability, dosing, resistance profile	Leader in protease inhibitors
Atazanavir	Once-daily dosing, fewer side effects	Significant market share
Lopinavir/Ritonavir	Established, combination formulations	Declining due to side effect profile
Fosamprenavir	Less used, newer agents more favored	Niche market

Market Drivers & Barriers

Drivers	Barriers
Rising prevalence of multi-drug resistant HIV strains	Limited conduction of new clinical trials
Existing formulations as salvage therapy options	Emergence of newer agents with better profiles
Developing markets with limited access to latest drugs	Patent expiry of initial formulations

Pricing & Reimbursement

Pricing	Average Wholesale Price (AWP)	Regional Variations
US (per 30-day supply)	~$2,500	Standard market pricing
EU	€2,100–€2,900	Varies by country
Emerging markets	Lower, often under government negotiation	Significantly reduced

Distribution & Supply Chain

• Manufacturers: Johnson & Johnson (previous licensee), now primarily distributed through third-party generic manufacturers in some regions.
• Supply constraints: Occasional manufacturing shortages reported due to complex formulation or regulatory issues.

---

Future Projections

Market Forecast (2023–2028)

Year	Predicted Global Revenue	CAGR	Comments
2023	~$62 million	—	Continuing decline
2024	~$55 million	-11%	Further narrowing use
2025	~$50 million	-9%	Slight stabilization among resistant pool
2026	~$45 million	-10%	Limited off-label and salvage use
2027	~$40 million	-11%	Market approaching niche status
2028	~$36 million	-10%	Declining; potential for new formulations in pipeline

Potential Growth Areas & Innovations

• Combination therapies: Limited exploratory trials with integrase inhibitors, possibly extending use.
• Formulation advancements: Preclinical research into long-acting injectables remains low but could revitalize interest.
• Repurposing for resistant HIV: Ongoing resistance studies might expand indications if new evidence emerges.

Regulatory & Policy Outlook

• Reduced focus by major regulatory agencies on new clinical trials for Tipranavir.
• Emphasis shifted toward generics, biosimilars, and novel agents.
• Potential for limited approval extensions in emerging markets for drug repurposing.

---

Comparison with Newer HIV Protease Inhibitors

Agent	Indication	Approval Year	Key Advantages	Market Share (2023)
Darunavir	HIV-1 Infection, Salvage therapy	2006	Better tolerated, lower resistance rate	~50% globally
Atazanavir	HIV-1 Infection	2003	Once daily, fewer lipid effects	~20%
Tipranavir	Multi-drug resistant HIV	2005	Efficacy in resistant strains	<3%

---

Deep-Dive Comparisons

Efficacy & Resistance Profile

Parameter	Tipranavir	Darunavir	Atazanavir
Resistance Barrier	High (effective against resistant strains)	Very high	Moderate
Viral Load Reduction	≥1.0 log10 in resistant HIV	≥1.5 log10 in resistant HIV	Similar or slightly lower
Resistance Development	Lower, but limited data	Little resistance reported	Resistance can develop over time

Safety & Tolerability

Parameter	Tipranavir	Darunavir	Atazanavir
Common Side Effects	Hepatotoxicity, intracranial hemorrhage risk	Rash, hyperglycemia, lipid ↑	Jaundice, hyperbilirubinemia

Dosing & Convenience

Agent	Dosing Schedule	Formulation	Dosing Frequency
Tipranavir	500 mg twice daily + ritonavir	Capsule	Twice daily
Darunavir	800 mg once daily or 600 mg BID	Tablet	Once or twice daily
Atazanavir	300 mg once daily	Capsule	Once daily

---

Key Takeaways

• Clinical Trials: No current advanced clinical trials for Tipranavir are underway, reflecting its mature status and limited scope for new indications.
• Market Position: Its role is confined primarily to salvage therapy for multi-drug resistant HIV, with declining market share due to newer agents.
• Market Outlook: The global HIV protease inhibitor market is expected to grow modestly (CAGR: ~4%), but Tipranavir’s contribution will likely diminish further, with forecasts indicating continued revenue decline.
• Competitive Advantage: High resistance barrier, but safety profile and convenience are inferior to newer agents, restricting its use.
• Innovation & Opportunities: Limited, mostly centered on niche applications and potential formulation improvements.

---

FAQs

1. What are the primary indications for Tipranavir treatment?
   Tipranavir is primarily prescribed for treatment-experienced HIV-1 patients with resistant viral strains, especially when other protease inhibitors fail.

2. Are there ongoing clinical trials for Tipranavir?
   As of Q1 2023, there are no active Phase 3 or Phase 4 trials; most studies have concluded from its initial approval, with current focus on post-marketing surveillance.

3. How does Tipranavir compare to newer HIV protease inhibitors?
   While Tipranavir demonstrates efficacy against resistant HIV strains, newer agents like Darunavir offer improved tolerability, dosing convenience, and resistance profiles, leading to its declining use.

4. What are the main challenges facing Tipranavir in the current market?
   Its safety concerns, limited patient base, competition from newer agents, and lack of ongoing R&D limit its growth prospects.

5. Could Tipranavir see a resurgence in the future?
   Unlikely unless new formulations, combination strategies, or resistance patterns emerge that revert its relevance in salvage therapy for resistant HIV.

---

References

1. FDA. (2005). FDA approval letter for Tipranavir (Aptivus).
2. European Medicines Agency. (2006). Summary of Product Characteristics for Tipranavir.
3. Statista. (2023). Global HIV medications market revenue and forecasts.
4. WHO. (2022). Global HIV/AIDS treatment guidelines.
5. ClinicalTrials.gov. (2023). Tipranavir-related clinical trials.